flosz schreef op 3 maart 2015 11:56:
And for diseases with very clear cost off-sets—in beta-thalassemia, for example, the cost of chronic blood transfusions and disease complications—payers will be more likely to see gene therapies as being cost effective, says Roger Longman, CEO of Real Endpoints, a New York–based information and analytics company focused on pharmaceutical reimbursement. And at the same time, “companies can make a bunch of money without gouging the system,” he says.